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vs. 62.2%, p= 0.24), but reported higher mean levels of absenteeism (12.64% vs. 5.00%, 
p= 0.0014), presenteeism (32.71% vs. 15.49%, p< 0.0001), overall work impairment 
(37.32% vs. 18.26%, p< 0.0001) and activity impairment (45.93 vs. 26.90, p< 0.0001) 
relative to controls. Mean health care utilization in the prior 6 months was greater 
among cases than controls for visits to traditional health care providers (8.39 vs. 
5.03, p< 0.0001), general practitioners (1.72 vs. 1.25, p= 0.0043), allergists (0.49 vs. 0.07, 
p< 0.0001), dermatologists (0.40 vs. 0.16, p= 0.0004), emergency rooms (0.50 vs. 0.33, 
p= 0.0608), and hospitalizations (0.36 vs. 0.23, p= 0.0985). ConClusions: Using CH 
as a proxy for CIU, a considerable economic burden on patients was evident in work 
productivity and use of health care compared to patients without CH with similar 
sociodemographic characteristics.
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objeCtives: To compare the number of 1st-line and 2nd-line intravitreal anti-
VEGF injections and associated costs in patients with neovascular age-related 
macular degeneration (AMD) treated with aflibercept (AFB) or ranibizumab 
(RBZ). Methods: A retrospective cohort study of US claims data of patients 
who: initiated 1st- or 2nd-line ITV anti-VEGF treatment with RBZ or AFB between 
1/18/2011 and 7/31/2013 (index date), had no evidence of bilateral disease, were 
aged ≥ 18 years on index date, had ≥ 12 months of continuous insurance enrollment 
before index date (baseline period), were diagnosed with AMD (ICD-9-CM 362.52) 
during baseline period or on index date, and had ≥ 12 months of follow-up enroll-
ment post index date without switching anti-VEGF agents. Outcomes (number of 
anti-VEGF injections and their associated costs) were assessed within 12-month 
follow-up period. Multivariable regressions compared outcomes between AFB and 
RBZ, adjusting for confounding patient characteristics. Results: A total of 115 
1st-line AFB, 431 2nd-line AFB, 481 1st-line RBZ, and 174 2nd-line RBZ patients met 
the inclusion criteria. Mean [SD] number of injections was similar for AFB and RBZ 
patients for 1st- (5.0 [2.7] and 5.0 [3.1], respectively) and 2nd-line (5.7 [2.5] and 5.8 
[3.1], respectively). Mean anti-VEGF therapy-related costs [SD] were comparable for 
AFB and RBZ patients for 1st- ($9,155 [$11,420] and $9,241 [$10,547], respectively) 
and 2nd-line ($10,485 [$11,734] and $10,935 [$13,411], respectively). Multivariable 
regression determined that, for both 1st- and 2nd-line patients, neither number 
nor costs of injections differed significantly between AFB and RBZ (treating RBZ 
as reference: Incidence Rate Ratio [IRR]= 0.99, 95% confidence interval [CI]= 0.87-
1.13, P= 0.871 [1st-line]; IRR= 0.97, 95%CI= 0.88-1.06, P= 0.476 [2nd-line]; Cost Ratio 
[CR]= 0.96, 95%CI= 0.82-1.11, P= 0.582 [1st-line]; CR= 0.89, 95%CI= 0.79-1.01, P= 0.064 
[2nd-line]). ConClusions: Injection frequency and costs over 12 months were 
similar for AFB and RBZ in this analysis of AMD patients initiating 1st- or 2nd-line 
anti-VEGF treatment in a real-world setting.
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objeCtives: The objective of this study was to describe health care costs associ-
ated with the management of psoriasis in patients newly initiated on a biologic 
or methotrexate (MTX). Methods: Continuously enrolled adult patients with ≥ 2 
inpatient or outpatient psoriasis diagnoses were selected from the MarketScan 
Commercial Claims database (2005-2009). The first biologic or MTX prescription 
date was defined as the index date. “MTX initiators” had not used biologics, non-
biologic conventional systemic therapies, or phototherapy 6 months before the 
index date. “Biologic initiators” were required to be biologic-naïve only before the 
index date. Health care costs were estimated from a US payer perspective (2011 
US dollars) over the 12-month period following the index date, based on payments 
for all medical services and psoriasis related diagnosis as a subset. Physician 
office visits, monitoring, inpatient hospitalizations, and emergency department 
visits were also captured. Results: A total of 2,642 MTX initiators and 6,702 bio-
logic initiators met the eligibility criteria. MTX initiators had a mean annual total 
health care cost of $12,548, of which 30.7% was psoriasis-related. Pharmacy costs 
accounted for $3,182 of the psoriasis-related costs, office care and monitoring 
costs accounted for $501, and urgent care costs accounted for $166. Biologic initia-
tors had an average annual total health care cost of $28,752, of which 72.0% was 
psoriasis-related. Pharmacy costs accounted for $19,997 of the psoriasis-related 
total costs, office care and monitoring cost for $538, and urgent care costs for 
$166. ConClusions: Psoriasis patients initiating on MTX or a biologic incurred 
substantial health care costs. Pharmacy costs account for the majority of the 
psoriasis-related costs.
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study worldwide investigating the burden of disease. Myopic CNV-related costs of 
care are substantial and increasing with the severity of vision loss.
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objeCtives: Estimate health care utilization and costs of co-morbidities in patients 
with psoriasis. Methods: A retrospective cohort analysis was conducted using 
the Truven MarketScan data®. Inclusion criteria were adult patients with at least 
2 diagnosis of psoriasis (ICD-9-CM: 696.1) on different dates between January 1st, 
2010 and December 31st, 2011, with at least one psoriasis diagnosis in year 2010 
and with continuous enrollment of medical and pharmacy benefits in year 2010 
and 2011. Patients were divided into two groups with and without comorbidity of 
interest in year 2010. Multiple regressions were conducted to compare all cause 
health care utilization (Poisson regression) and costs (gamma regression or two 
part models; 95% confidence intervals (CI) were calculated using bootstrapping 
method) in year 2011 between patients with and without comorbidity of interest, 
controlling for age, gender, and region and psoriasis severity in year 2010. Results: 
A total of 56,406 patients (mean age 51.71 years) were included in the analyses. 
The top five prevalent co-morbidities were hypertension (34.49%), hyperlipidemia 
(33.79%), cardiovascular disease (17.44%), diabetes (14.36%) and psoriatic arthritis 
(9.94 %). The all cause incidence rate ratio (95% CI) of emergency room visits, hos-
pitalization, outpatient visits for patients with at least one co-morbidity was 1.84 
(1.75-1.94); 2.03 (1.87-2.19); 1.49 (1.47-1.51) respectively compared to patients with 
no co-morbidities (all, p< 0.0001). The adjusted all cause health care costs difference 
was $6640 ($6255-$7024) for patients with co-morbidities as compared patients 
with no co-morbidities. The mean (95% CI) all cause adjusted cost difference for 
psoriatic patients with co-morbidities as compared to psoriatic patients without co-
morbidities was $4,522 ($4034-$5011), $1,635 ($1,188-$2,082), $8,275.1 ($7,461-$9,089), 
$6,911 ($6,271-$7,552) and $9,914 ($9,216-$10,613) for hypertension, hyperlipidemia, 
cardiovascular disease, diabetes and psoriatic arthritis respectively. ConClusions: 
Comorbidities continue to have a significant economic burden in patients with 
psoriasis in the United States.
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objeCtives: Estimate direct and indirect costs of depression and anxiety in 
patients with psoriasis (PsO). Methods: Retrospective cohort analysis was con-
ducted using Truven MarketScan data®. Adult patients with at least 2 diagnosis of 
PsO (ICD-9-CM: 696.1) between year 2010 and 2011 (at least one PsO diagnosis in 
year 2010) having continuous enrollment of medical and pharmacy benefits were 
included. Patients with Health and Productivity Management data for 2011 were 
included for the indirect cost analysis, including costs associated with absence 
of leave (ABS), short term disability (STD), and long term disability (LTD). Indirect 
costs were calculated using average 2011 hourly wage data for all US private indus-
tries (number of ABS/STD/LTD days * 8 hours * an average hourly wage). Multiple 
regressions were conducted to compare year 2011 direct costs and indirect costs 
(gamma regression or two part models) between patients with and without depres-
sion or anxiety respectively, controlling for age, gender, and region and PsO sever-
ity in year 2010. Results: Among a total of 56,406 PsO patients (mean age 52 
years), 7.9% patients with depression and 5.7% with anxiety in year 2010 were 
included in the direct cost analyses. A total of 1,434 patients for ABS, 5,878 for 
STD and 5,692 for LTD were included in the indirect cost analyses. The adjusted 
health care costs were significantly higher for patients with depression ($20,794 
vs. $14,028) or anxiety ($18,501 vs. $14,320) than those without (p< 0.001 for all). 
The major differences between indirect costs were STD costs whereby the adjusted 
mean difference between patients with depression vs. without depression were 
$997 (95% confidence interval (CI) $432-1561), between patients with anxiety vs. 
without was $268 (95% CI $-158-790). ConClusions: Significant proportion of PsO 
patients had depression and anxiety, and patients with depression and anxiety 
have substantial higher direct and indirect costs than those without.
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objeCtives: To assess the economic burden of patients with chronic idiopathic 
urticaria (CIU) in terms of labor force participation, work and activity impairment, 
and health care utilization, using patients currently treated for chronic hives 
(CH) as a proxy. Methods: Data were obtained from the US National Health and 
Wellness Survey (NHWS) in 2010-2012, representative of US adult population in 
terms of age, sex, and ethnicity. Measures included labor force participation, the 
Work Productivity and Activity Impairment questionnaire, and self-reported health 
care use in the prior 6 months. Respondents indicating current use of a prescrip-
tion for CH (cases) were matched 1:4 to those who never experienced CH (controls), 
using survey year, sex, race, age (±2 years), and Charlson comorbidity index (CCI) 
category (0, 1-2, 3-4, or 5+), and compared using t-test and chi-square. Results: 
Cases (n= 253) and controls (n= 1,012) did not significantly differ in terms of age, 
body mass index, marital status, educational attainment, or mean CCI (all p> 0.05). 
Currently-treated CH patients participated in the labor force at a similar rate (58.1% 
